Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

被引:0
|
作者
Cheng, H. [1 ,2 ]
Chen, J. [1 ,2 ]
Jia, G. [1 ,2 ]
Liang, Y. [1 ,2 ]
Li, Y. [1 ,2 ]
Chen, Y. [1 ,2 ]
Lin, J. [1 ,2 ]
Wang, P. [1 ,2 ]
Chen, Q. [1 ,2 ]
Tang, L. [1 ,2 ]
Mai, H. [1 ,2 ]
Liu, L. [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Key Lab Nasopharyngeal Carcinoma Diag & Therapy, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China
关键词
locoregionally advanced nasopharyngeal carcinoma; adjuvant chemotherapy initiation; optimal timing; progression-free survival; RANDOMIZED-TRIAL; STAGE-III; CANCER; SURVIVAL; RADIOTHERAPY; ASSOCIATION; MULTICENTER; TIME; DNA;
D O I
10.1016/j.esmoop.2024.103707
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Studies on several malignancies have suggested that the time to commencement of adjuvant chemotherapy (AC) is associated with survival outcomes. There have, however, been no relevant reports of nasopharyngeal carcinoma (NPC). Patients and methods: This clinical study examined newly diagnosed patients between April 2017 and December 2020. The primary endpoint was progression-free survival (PFS). Inverse probability of treatment weighting was used to control for confounding factors. Cox models with restricted cubic splines, Kaplan-Meier method and log-rank tests were used to evaluate the relationship between AC timing and survival. Results: A total of 551 patients were identified [median age, 45 years (interquartile range 36-52 years); 383 (69.5%) male]. Restricted cubic splines demonstrated that the timing of AC initiation had a U-shaped association with PFS. The risk of disease progression decreased within 37 days and subsequently increased. From 37 to 90 days, each additional 7-day delay conferred worse PFS of 1.32 months {hazard ratio (HR): 1.14 [95% confidence interval (CI) 1.01-1.28], P = 0.04}. The cut-off value of the receiver operating characteristic curve for initiation was 69.5 days. At a median follow-up of 48 months, the PFS was significantly better in patients initiated within 69.5 days [HR: 2.18 (95% CI 1.17-4.06), log-rank P = 0.009], with a higher 3-year rate [78.8% (95% CI 75.1% to 82.7%) versus 59.0% (95% CI 42.2% to 82.5%)] than beyond 69.5 days. Positive results were also observed in secondary endpoints. The initiation group was an independent prognostic factor [HR: 2.28 (95% CI 1.42-3.66), P < 0.001]. Conclusions: The optimal timing of AC initiation is similar to 37 days after concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. A delay beyond 69.5 days is associated with compromised survival. Efforts should be made to address the reasons for delays and ensure the timely initiation of AC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma
    Zhang, Wendong
    Dou, Huiqin
    Lam, Chileong
    Liu, Jixi
    Zhou, Jianfeng
    Liu, Yunsheng
    Wang, Xiuwen
    TUMOR BIOLOGY, 2013, 34 (03) : 1729 - 1736
  • [2] The role of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma
    Lee, K.
    Hee, S.
    Wee, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S424 - S425
  • [3] Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers
    Tao, Hao-Yun
    He, Fang
    Shi, Qi-Yun
    Liu, Ran
    Wang, Zhi-Long
    Du, Kun-Peng
    Li, Jian-Feng
    Liu, Hui
    Lu, Zhi-Qiang
    Zhang, Jing-Jing
    Bai, Yu-Hai
    CANCER MEDICINE, 2023, 12 (06): : 6811 - 6824
  • [4] The Clinical Outcomes and Toxicities of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
    Zou, Rui
    Yuan, Jing-Jing
    Li, Qiang
    Ding, Jian-Wu
    Liao, Bing
    Tu, Zi-Wei
    Hu, Rong-Huan
    Gong, Dan
    Hu, Jia-Li
    Zeng, Lei
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [5] Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
    Mu, Xiaoli
    Liu, Hongyan
    Wu, Juan
    Chen, Shi
    Peng, Xingchen
    Wang, Jingjing
    Wei, Zhigong
    He, Ling
    Liu, Jiyan
    Lu, Zejun
    Su, Yonglin
    AGING-US, 2022, 14 (16): : 6727 - 6739
  • [6] Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma A matched-pair multicenter analysis of outcomes
    Dong, Yi-Yuan
    Xiang, Chun
    Lu, Jian-Xun
    Su, Yi-Xin
    Pan, Yu-Fei
    Cai, Rui
    Zhang, Rong-Jun
    He, Zhuo-Kai
    Liu, Mei-Lian
    Huang, Hui
    Bai, Xue
    Tang, Hua-Ying
    Shi, Yun-Hua
    Wang, Yan
    Jiang, Wei
    STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 (06) : 394 - 402
  • [7] Evaluation of Adjuvant Chemotherapy after Induction Chemotherapy and Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: A Propensity Score-Matched Analysis
    He, Y.
    Li, Y.
    Tang, Q.
    Ma, S.
    Xiong, Z.
    Huang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E758 - E758
  • [8] Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma
    Feng, Hui-Xia
    Guo, Su-Ping
    Li, Gui-Rong
    Zhong, Wen-Huan
    Chen, Liu
    Huang, Li-Ru
    Qin, Hui-Ying
    MEDICAL ONCOLOGY, 2014, 31 (09) : 1 - 6
  • [9] Concurrent Chemoradiotherapy (CCRT) followed by adjuvant chemotherapy (CTX) in the treatment of locoregionally advanced undifferentiated carcinoma of nasopharyngeal type (UCNT)
    Bacoyiannis, Charalabos
    Katsikas, Michael
    Klouvas, George
    Matsouka, Fotini
    Kolitsi, Georgia
    Katsohi, Despina
    Kyprianou, Costas
    Skarlos, Dimosthenis
    Kosmidis, Paris
    ANNALS OF ONCOLOGY, 2004, 15 : 141 - 141
  • [10] Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma
    Hui-Xia Feng
    Su-Ping Guo
    Gui-Rong Li
    Wen-Huan Zhong
    Liu Chen
    Li-Ru Huang
    Hui-Ying Qin
    Medical Oncology, 2014, 31